Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors while in the central anxious system, conolidine modulates alternate molecular targets. A Science Developments review found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://warrenv553pyg3.wikibyby.com/user